Christopher B. Nahm

Jan 9, 2025 | onlinelibrary.wiley.com | Sooin Byeon |Christopher B. Nahm |John Turchini |Nathalie B. Rasko

FFPE formalin-fixed paraffin-embedded FXYD3 FXYD domain-containing ion transport regulator MAT-8 mammary tumour protein 8 PDAC pancreatic ductal adenocarcinoma TMA tissue microarrays 1 Introduction Pancreatic ductal adenocarcinoma (PDAC) continues to pose a significant clinical challenge with a five-year survival rate of only ~8% and marginal improvements over several decades [1, 2].

Aug 2, 2023 | onlinelibrary.wiley.com | Sumit Sahni |Christopher B. Nahm |Mahsa Ahadi |Sooin Byeon

RESEARCH ARTICLE Sumit Sahni and Anubhav Mittal contributed equally as senior and co-corresponding authors. Abstract Aim Pancreatic ductal adenocarcinoma (PDAC) has the lowest survival rate of all major cancers. Chemotherapy is the mainstay systemic therapy for PDAC, and chemoresistance is a major clinical problem leading to therapeutic failure. This study aimed to identify key differences in gene expression profile in tumors from chemoresponsive and chemoresistant patients.